急性脑梗死患者超早期阿替普酶静脉溶栓效果及好转后恶化的影响因素分析

doi:10.3969/j.issn.1671-7171(2018)06.025

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】分析急性脑梗死(ACI)患者超早期阿替普酶(rt-PA)静脉溶栓效果及好转后恶化的影响因素分析。【方法】选择2014年1月至2016年12月于本院行超早期rt-PA治疗的70例ACI患者作为观察组,同期选择采用常规治疗的ACI患者90例作为对照组。分别于治疗前后对患者神经功能缺损情况〔采用美国国立卫生研究院卒中量表(NIHSS)评定〕、预后情况〔Barthel指数(BI)及改良Rankin量表(mRS)〕进行评价,并统计两组并发症发生率;同时将行rt-PA治疗的观察组患者按其溶栓好转后是否恶化分为恶化组(n=9)及未恶化组(n=71),收集患者人口学、既往史、实验室指标等临床资料进行单因素分析,再筛选单因素分析有差异选项行多因素Logistic回归分析,探讨静脉溶栓好转后恶化的独立危险因素。【结果】治疗前,两组患者NIHSS评分、BI指数及mRS评分行组间比较,差异均无统计学意义(P＞0.05);治疗后,两组患者NIHSS评分、BI指数及mRS评分均得到显著改善,且观察组各评分指标的改善幅度均优于对照组,差异有统计学意义(P＜0.05)。经多变量Logistic回归分析,高龄、既往房颤史、溶栓时间晚、溶栓前NIHSS评估高、白细胞计数低、完全前循环梗死均为ACI超早期rt-PA静脉溶栓好转后恶化的独立危险因素。【结论】ACI超早期rt-PA静脉溶栓能通过其溶栓机制快速纠正脑组织缺血、缺氧状态,并挽救受损神经功能,但针对溶栓治疗好转后恶化的独立危险因素也应给予高度重视。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张洪
	王燕萍
	王红磊

关键词 ：脑梗死/药物疗法, 组织型纤溶酶原激活物/药物作用, 危险因素

Abstract：【Objective】To analyze the effects of ultra-early alteplase (rt-PA) intravenous thrombolysis in patients with acute cerebral infarction (ACI) and the influencing factors of deterioration after improvement. 【Methods】A total of 70 patients with ACI treated by rt-PA intravenous thrombolysis in our hospital from January 2014 to December 2016 were selected as the observation group, and 90 patients with ACI in the same period who only received conventional treatment were selected as the control group. The status of neurological impairment was evaluated with the National Institutes of Health Stroke Scale (NIHSS) and the prognosis was evaluated with the Barthel index (BI) and modified Rankin scale (mRS). The incidence of complications was statistically analyzed. Furthermore, patients in the observation group were divided into the deterioration group (n=9) and the non-deterioration group (n=71). The clinical data were collected for univariate analysis and factors with significant differences were analyzed by logistic regression analysis. 【Results】Before treatment, there were no significant differences between the two groups in NIHSS score, BI and mRS scores, while after treatment, the above-mentioned indexes were significantly improved and the improvement was more obvious in the observation group than the control group. Multivariable logistic regression analysis showed that age, previous history of atrial fibrillation, late thrombolysis, high NIHSS score before thrombolysis, low white blood cell count and total anterior circulation infarction were independent risk factors for deterioration after improvement. 【Conclusion】Ultra-early rt-PA intravenous thrombolysis can quickly correct the status of cerebral ischemia and hypoxia and save the damaged neurological function in patients with ACI. Attention should be paid to the independent risk factors for deterioration after improvement.

Key words： BrainInfarction/DT TissuePlasminogenActivator/DE TreatmentOutcome RiskFactors

收稿日期: 2017-09-30

PACS:

R743.33

引用本文:

张洪, 王燕萍, 王红磊. 急性脑梗死患者超早期阿替普酶静脉溶栓效果及好转后恶化的影响因素分析[J]. 医学临床研究, 2018, 35(6): 1115-1119.
ZHANG Hong, WANG Yan-ping, WANG Hong-lei. Effects of Ultra-early Alteplase Intravenous Thrombolysis in Patients with Acute Cerebral Infarction and the Influencing Factors of Deterioration after Improvement. JOURNAL OF CLINICAL RESEARCH, 2018, 35(6): 1115-1119.

链接本文:

http://www.jcr.net.cn/CN/10.3969/j.issn.1671-7171(2018)06.025 或 http://www.jcr.net.cn/CN/Y2018/V35/I6/1115

[1] 金涛, 朱广军, 韩光李凤昌,等. 亚急性期脑梗死患者数字减影全脑血管造影致脑栓塞的危险因素分析[J]. 湖南师范大学学报(医学版), 2015, 20(1):98-100.
[2] 唐海源, 邹永彪, 张春华,等. 阿替普酶静脉溶栓治疗心源性脑栓塞31例临床疗效[J]. 医学临床研究, 2015,32(2):320-322.
[3] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010, 43(2):16-19.
[4] 中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4):246-257.
[5] 黄镪, 马青峰, 冯娟,等. 急性缺血性卒中静脉溶栓决策的影响因素[J]. 中国脑血管病杂志, 2016, 13(1):13-16.
[6] 李艳琴, 刘斌, 李世英,等. 急性脑梗死病因分型及进展[J]. 中国煤炭工业医学杂志, 2015,18(7):1247-1252.
[7] 朱方方, 张友好, 冯敏,等. 同型半胱氨酸、超敏C反应蛋白、低密度脂蛋白、三酰甘油、总胆固醇与急性脑梗死的关系研究[J]. 蚌埠医学院学报, 2016, 41(5):623-625.
[8] 刘静, 吴雅坤. 急性脑梗死rt-PA溶栓治疗进展[J]. 河北医科大学学报, 2016, 37(3):355-357.
[9] 刘璇, 李秀荣, 闻红斌,等. 急性脑梗死患者静脉溶栓后出现出血转化的危险因素分析[J]. 医学综述, 2016, 22(6):1228-1230.
[10] 李婷婷, 郝应禄, 李燕萍,等. 低分子肝素在阿替普酶溶栓治疗中的应用[J]. 昆明医科大学学报, 2016, 37(5):93-96.
[11] 薛桦. 尿激酶与阿替普酶治疗急性脑梗死的疗效对比[J]. 药物评价研究, 2016, 39(5):828-831.
[12] 鲁文先, 苏毅鹏, 陈金波,等. 急性脑梗死患者阿替普酶静脉溶栓的疗效及出血性转化影响因素分析[J]. 脑与神经疾病杂志, 2017, 25(1):29-33.
[13] 钟建斌, 沈庆煜, 陈炽邦,等. 超高龄脑梗死患者超早期应用阿替普酶静脉溶栓治疗的效果及安全性[J]. 实用医学杂志, 2016, 32(7):1058-1060.
[14] 崔颖, 佟旭, 王伊龙,等. 急性缺血性卒中患者阿替普酶静脉溶栓后发生早期神经功能恶化的危险因素分析[J]. 中华神经科杂志, 2016, 49(12):925-931.
[15] 李克良, 耿瑞慧, 朱立勋,等. 影响阿替普酶治疗急性缺血性卒中早期疗效的临床研究[J]. 现代生物医学进展, 2017, 17(8):1464-1467.